Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Обзорная статья

Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application

Jing XieSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, ChinaYe BiPractice Training Center, Changchun University of Chinese Medicine, Changchun, ChinaHuan ZhangSchool of Life Sciences, Jilin University, Changchun, ChinaShiyan DongSchool of Life Sciences, Jilin University, Changchun, ChinaLesheng TengSchool of Life Sciences, Jilin University, Changchun, ChinaRobert J. LeeDivision of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, OH, United StatesZhaogang YangDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States
2020en
ABI

Аннотация

Cell-penetrating peptides (CPPs) are short peptides (fewer than 30 amino acids) that have been predominantly used in basic and preclinical research during the last 30 years. Since they are not only capable of translocating themselves into cells but also facilitate drug or CPP/cargo complexes to translocate across the plasma membrane, they have potential applications in the disease diagnosis and therapy, including cancer, inflammation, central nervous system disorders, otologic and ocular disorders, and diabetes. However, no CPPs or CPP/cargo complexes have been approved by the US Food and Drug Administration (FDA). Many issues should be addressed before translating CPPs into clinics. In this review, we summarize recent developments and innovations in preclinical studies and clinical trials based on using CPP for improved delivery, which have revealed that CPPs or CPP-based delivery systems present outstanding diagnostic therapeutic delivery potential.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 3Использованных источников: 0